Brought to you by 
Novelos buys Cellectar
20 May 2011
Executive Summary
Struggling oncology therapeutics company Novelos Therapeutics Inc. has purchased privately held Cellectar Inc. (cancer-targeted drugs) in an all-stock transaction. Novelos issued 85% of its outstanding stock (post-acquisition) to Cellectar shareholders, or about 17mm shares after giving effect to a 1 for 153 reverse stock split conducted by Novelos with the closing of the merger. Based on the adjusted ten-day market average prior to the transaction (and considering the stock split), the deal is valued at $44mm.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
- Payment Includes Stock
- Reverse Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novelos buys Cellectar
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice